首页 > 最新文献

The Journal of dermatological treatment最新文献

英文 中文
The efficacy of combined phototherapy with topical therapy in vitiligo: a network meta-analysis. 光疗联合局部治疗白癜风的疗效:网络荟萃分析。
Pub Date : 2025-12-01 Epub Date: 2025-04-08 DOI: 10.1080/09546634.2025.2483808
Liping Luo, Jinhua Huang, Chuhan Fu, Yibo Hu, Jing Chen, Ling Jiang, Qinghai Zeng

Background: The comparative effects of phototherapy and topical therapy in patients with vitiligo remain unclear. A network meta-analysis (NMA) was conducted to assess which combination therapy was more beneficial for patients with vitiligo.

Methods: This study analyzed phototherapy, including narrowband ultraviolet B (NB-UVB) and 308-nm excimer laser/light (EL) combined with topical therapies. Randomized controlled trials were sourced from PubMed, Embase, and Cochrane Library. Data analysis was based on a random-effects model, and surface under the cumulative ranking (SUCRA) curves employed to assess the efficacy of the interventions.

Results: This NMA included 27 trials, with a total of 2417 lesions (patches). According to the results of the SUCRA, for achieving ≥50% repigmentation, the top three combination therapies were phototherapy combined with antioxidants (SUCRA 87.7), corticosteroids (SUCRA 69.6), and calcineurin inhibitors (SUCRA 52.5), while for ≥75% repigmentation, the leading therapies were phototherapy combined with antioxidants (SUCRA 89.0), calcineurin inhibitors (SUCRA 70.3), and fractional CO2 laser (SUCRA 63.6).

Conclusions: This meta-analysis suggests that combining phototherapy with topical antioxidants, corticosteroids, or calcineurin inhibitors may offer superior outcomes for vitiligo patients. This study provides a reference for clinicians to develop personalized treatment plans for patients with vitiligo.

背景:光疗和外用疗法对白癜风患者的疗效比较仍不明确。为了评估哪种综合疗法对白癜风患者更有益,我们进行了一项网络荟萃分析(NMA):本研究分析了光疗,包括窄带紫外线B(NB-UVB)和308纳米准分子激光/光(EL)与局部疗法的结合。随机对照试验来自 PubMed、Embase 和 Cochrane 图书馆。数据分析基于随机效应模型,并采用累积排名曲线(SUCRA)来评估干预措施的疗效:该 NMA 包括 27 项试验,共有 2417 个病灶(斑块)。根据SUCRA的结果,对于达到≥50%的再色素沉着率,排名前三位的联合疗法分别是光疗联合抗氧化剂(SUCRA 87.7)、皮质类固醇激素(SUCRA 69.6)和钙化蛋白抑制剂(SUCRA 52.5),而对于≥75%的再色素沉着,主要疗法是光疗联合抗氧化剂(SUCRA 89.0)、钙调磷酸酶抑制剂(SUCRA 70.3)和点阵二氧化碳激光(SUCRA 63.6):这项荟萃分析表明,将光疗与局部抗氧化剂、皮质类固醇激素或钙调素抑制剂结合使用,可能会为白癜风患者带来更好的治疗效果。这项研究为临床医生为白癜风患者制定个性化治疗方案提供了参考。
{"title":"The efficacy of combined phototherapy with topical therapy in vitiligo: a network meta-analysis.","authors":"Liping Luo, Jinhua Huang, Chuhan Fu, Yibo Hu, Jing Chen, Ling Jiang, Qinghai Zeng","doi":"10.1080/09546634.2025.2483808","DOIUrl":"10.1080/09546634.2025.2483808","url":null,"abstract":"<p><strong>Background: </strong>The comparative effects of phototherapy and topical therapy in patients with vitiligo remain unclear. A network meta-analysis (NMA) was conducted to assess which combination therapy was more beneficial for patients with vitiligo.</p><p><strong>Methods: </strong>This study analyzed phototherapy, including narrowband ultraviolet B (NB-UVB) and 308-nm excimer laser/light (EL) combined with topical therapies. Randomized controlled trials were sourced from PubMed, Embase, and Cochrane Library. Data analysis was based on a random-effects model, and surface under the cumulative ranking (SUCRA) curves employed to assess the efficacy of the interventions.</p><p><strong>Results: </strong>This NMA included 27 trials, with a total of 2417 lesions (patches). According to the results of the SUCRA, for achieving ≥50% repigmentation, the top three combination therapies were phototherapy combined with antioxidants (SUCRA 87.7), corticosteroids (SUCRA 69.6), and calcineurin inhibitors (SUCRA 52.5), while for ≥75% repigmentation, the leading therapies were phototherapy combined with antioxidants (SUCRA 89.0), calcineurin inhibitors (SUCRA 70.3), and fractional CO<sub>2</sub> laser (SUCRA 63.6).</p><p><strong>Conclusions: </strong>This meta-analysis suggests that combining phototherapy with topical antioxidants, corticosteroids, or calcineurin inhibitors may offer superior outcomes for vitiligo patients. This study provides a reference for clinicians to develop personalized treatment plans for patients with vitiligo.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2483808"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations. 在植发手术中使用大麻对局部麻醉剂剂量的影响:病例报告、拟议机制和临床建议。
Pub Date : 2025-12-01 Epub Date: 2025-03-26 DOI: 10.1080/09546634.2025.2482009
Aditya K Gupta, Mesbah Talukder, Sharon A Keene

Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.

大麻的使用在过去十年中显著增加。这篇文章提出了一个病例,病人需要更多的局部麻醉(LA)比平常诱导有效的麻醉在头发移植手术。人们对大麻使用者经常需要更多的洛杉矶的原因知之甚少。一种可能是大麻的戒断效应使患者对疼痛和压力更敏感。此外,大麻的血管舒张特性可能会加速LA从应用部位的清除。两种主要的大麻素,大麻二酚(CBD)和四氢大麻酚(THC)与大麻素受体1 (CB1)、大麻素受体2 (CB2)和瞬时受体电位香草素1 (TRPV1)受体的相互作用也很复杂。此外,CBD和THC作为细胞色素P450酶抑制剂可能影响全身代谢。当计划在大麻使用者毛发修复手术期间使用LA时,临床医生应获得详细的既往消费史(大麻类型,频率,剂量)。术前计划应考虑预期手术时间,并计算最大安全剂量,以避免毒性风险。此外,在手术过程中应仔细监测患者的生命体征。如果患者需要频繁再注射以保持无疼痛,外科医生可能需要重新评估手术计划以避免毒性。
{"title":"The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations.","authors":"Aditya K Gupta, Mesbah Talukder, Sharon A Keene","doi":"10.1080/09546634.2025.2482009","DOIUrl":"10.1080/09546634.2025.2482009","url":null,"abstract":"<p><p>Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2482009"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial. 斑秃患者头皮毛发再生后患者报告的结果改善:ALLEGRO-2b/3试验分析
Pub Date : 2025-12-01 Epub Date: 2025-02-03 DOI: 10.1080/09546634.2025.2460577
Ernest H Law, Kent A Hanson, Matthew Harries, Dane Korver, Bintu Sherif, Costel Chirila

Purpose: Alopecia areata (AA), an autoimmune disorder characterized by non-scarring hair loss, is detrimental to the psychological health and quality of life of people living with AA. Clinically meaningful hair regrowth is possible, but the relationship with downstream patient-reported outcomes (PROs) is complex.

Materials and methods: This post hoc analysis of ALLEGRO-2b/3 (NCT03732807) longitudinal data from Weeks 24-48 compared improvements in PROs between patients who achieved (responders) or did not achieve (non-responders) clinically meaningful scalp hair regrowth. Responders were defined by a Week 24 Severity of Alopecia Tool (SALT) score ≤20 (SALT20) or ≤10 (SALT10). Across 6 PROs assessing multiple AA-related health domains, response proportions and mean changes from baseline were estimated for Weeks 24-48.

Results: Among 650 included participants, 114 (17.5%) were SALT20 responders, of which 76 (11.7%) were also SALT10 responders. Generally, more responders than non-responders reported improvements in AA and related symptoms or limitations and satisfaction with hair regrowth. Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations.

Conclusions: These results support a positive relationship between scalp hair regrowth and downstream PROs-including satisfaction and psychosocial burden-demonstrating an association between clinically meaningful hair regrowth and patient-reported treatment benefits.

目的:斑秃(AA)是一种以非瘢痕性脱发为特征的自身免疫性疾病,对AA患者的心理健康和生活质量有害。有临床意义的头发再生是可能的,但与下游患者报告的结果(PROs)的关系是复杂的。材料和方法:这项对ALLEGRO-2b/3 (NCT03732807)纵向数据的事后分析比较了实现(应答)和未实现(无应答)有临床意义的头皮再生的患者之间PROs的改善。根据第24周脱发严重程度评分≤20 (SALT20)或≤10 (SALT10)来定义应答者。在评估多个aa相关健康领域的6个pro中,估计了24-48周的响应比例和基线的平均变化。结果:在650名纳入的参与者中,114名(17.5%)是SALT20应答者,其中76名(11.7%)也是SALT10应答者。一般来说,应答者比无应答者更多地报告了AA的改善和相关症状或限制以及对头发再生的满意度。此外,在aa相关的情绪症状、心理健康、工作或活动限制方面,应答者比无应答者报告的基线改善更大。结论:这些结果支持头皮头发再生与下游pro(包括满意度和心理社会负担)之间的正相关,表明临床意义的头发再生与患者报告的治疗益处之间存在关联。
{"title":"Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial.","authors":"Ernest H Law, Kent A Hanson, Matthew Harries, Dane Korver, Bintu Sherif, Costel Chirila","doi":"10.1080/09546634.2025.2460577","DOIUrl":"10.1080/09546634.2025.2460577","url":null,"abstract":"<p><p><b>Purpose:</b> Alopecia areata (AA), an autoimmune disorder characterized by non-scarring hair loss, is detrimental to the psychological health and quality of life of people living with AA. Clinically meaningful hair regrowth is possible, but the relationship with downstream patient-reported outcomes (PROs) is complex.</p><p><p><b>Materials and methods:</b> This post hoc analysis of ALLEGRO-2b/3 (NCT03732807) longitudinal data from Weeks 24-48 compared improvements in PROs between patients who achieved (responders) or did not achieve (non-responders) clinically meaningful scalp hair regrowth. Responders were defined by a Week 24 Severity of Alopecia Tool (SALT) score ≤20 (SALT20) or ≤10 (SALT10). Across 6 PROs assessing multiple AA-related health domains, response proportions and mean changes from baseline were estimated for Weeks 24-48.</p><p><p><b>Results:</b> Among 650 included participants, 114 (17.5%) were SALT20 responders, of which 76 (11.7%) were also SALT10 responders. Generally, more responders than non-responders reported improvements in AA and related symptoms or limitations and satisfaction with hair regrowth. Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations.</p><p><p><b>Conclusions:</b> These results support a positive relationship between scalp hair regrowth and downstream PROs-including satisfaction and psychosocial burden-demonstrating an association between clinically meaningful hair regrowth and patient-reported treatment benefits.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2460577"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of double-layer artificial dermis repair material combined with autologous skin patch in repairing deep skin and soft tissue defects: a retrospective study. 双层人工真皮修复材料联合自体皮肤贴片修复深层皮肤软组织缺损的回顾性研究。
IF 3.9 Pub Date : 2025-12-01 Epub Date: 2025-08-12 DOI: 10.1080/09546634.2025.2541970
Yuhuai Xu, Yan Liu, Peng Cao, Jiaxing Chen, Bingrun Li, Yu Wang, Litao Zhang, Shujing Liu

Objectives: With the development of biotechnology, double-layer artificial dermis repair material has been increasingly employed to repair deep skin and soft tissue defects. This study aims to investigate the effectiveness of double-layer artificial dermis repair material combined with autologous skin patch in repairing deep skin and soft tissue defects.

Methods: This study conducted a retrospective analysis of 18 patients with deep skin and soft tissue defects who were treated with a combination of double-layer artificial dermal repair materials and autologous skin grafting at our hospital between January 2022 and January 2024.

Results: A total of 18 patients were treated, including 7 males and 11 females, with an average age of 41.7 ± 19.12 years. All patients exhibited good vascularization of the double-layer artificial dermal material postoperatively. In one patient, only a small part of the autologous skin patch survived after the first grafting, and the skin healed well after the second grafting. The remaining patients healed well after the operation. Two months after the operation, the results showed that no obvious hyperplastic contracture scar was found in the wound grafts of 18 patients, and the total Vancouver Scar Scale (VSS) score was not significantly different between 1 month and 2 months after the operation (p > 0.05).

Conclusion: Double-layer artificial dermis repair material combined with autologous skin patch provides a reliable, less invasive and simple treatment for deep skin and soft tissue defects.

目的:随着生物技术的发展,双层人工真皮修复材料越来越多地用于修复皮肤深层和软组织缺损。本研究旨在探讨双层人工真皮修复材料联合自体皮肤贴片修复深层皮肤软组织缺损的效果。方法:回顾性分析我院2022年1月至2024年1月间采用双层人工真皮修复材料联合自体皮肤移植术治疗深层皮肤软组织缺损的18例患者。结果:共治疗18例患者,其中男性7例,女性11例,平均年龄41.7±19.12岁。所有患者术后均表现出良好的双层人工真皮血管化。1例患者第一次植皮后只有一小部分自体皮肤贴片存活,第二次植皮后皮肤愈合良好。其余患者术后愈合良好。术后2个月,18例患者创面移植物未见明显增生挛缩瘢痕,术后1个月与2个月温哥华瘢痕评分(VSS)总分差异无统计学意义(p < 0.05)。结论:双层人工真皮修复材料联合自体皮肤贴片治疗深层皮肤软组织缺损可靠、微创、简便。
{"title":"Effectiveness of double-layer artificial dermis repair material combined with autologous skin patch in repairing deep skin and soft tissue defects: a retrospective study.","authors":"Yuhuai Xu, Yan Liu, Peng Cao, Jiaxing Chen, Bingrun Li, Yu Wang, Litao Zhang, Shujing Liu","doi":"10.1080/09546634.2025.2541970","DOIUrl":"10.1080/09546634.2025.2541970","url":null,"abstract":"<p><strong>Objectives: </strong>With the development of biotechnology, double-layer artificial dermis repair material has been increasingly employed to repair deep skin and soft tissue defects. This study aims to investigate the effectiveness of double-layer artificial dermis repair material combined with autologous skin patch in repairing deep skin and soft tissue defects.</p><p><strong>Methods: </strong>This study conducted a retrospective analysis of 18 patients with deep skin and soft tissue defects who were treated with a combination of double-layer artificial dermal repair materials and autologous skin grafting at our hospital between January 2022 and January 2024.</p><p><strong>Results: </strong>A total of 18 patients were treated, including 7 males and 11 females, with an average age of 41.7 ± 19.12 years. All patients exhibited good vascularization of the double-layer artificial dermal material postoperatively. In one patient, only a small part of the autologous skin patch survived after the first grafting, and the skin healed well after the second grafting. The remaining patients healed well after the operation. Two months after the operation, the results showed that no obvious hyperplastic contracture scar was found in the wound grafts of 18 patients, and the total Vancouver Scar Scale (VSS) score was not significantly different between 1 month and 2 months after the operation (<i>p ></i> 0.05).</p><p><strong>Conclusion: </strong>Double-layer artificial dermis repair material combined with autologous skin patch provides a reliable, less invasive and simple treatment for deep skin and soft tissue defects.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2541970"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abrocitinib combined with low-dose corticosteroids in the management of tattoo-related cutaneous sarcoidosis: a case report. 阿布替尼联合低剂量皮质类固醇治疗纹身相关皮肤结节病1例
IF 3.9 Pub Date : 2025-12-01 Epub Date: 2025-09-04 DOI: 10.1080/09546634.2025.2556487
Qingwei Geng, Junzhu Xu

Purpose: Sarcoidosis is a chronic, multisystem granulomatous disorder characterized histologically by non-caseating granulomas. Despite the availability of various therapeutic options, long-term disease control remains a significant clinical challenge.

Materials and methods: We report the case of a 55-year-old female diagnosed with sarcoidosis. Skin and lymph node biopsies revealed non-caseating granulomatous inflammation, and chest CT indicated pulmonary involvement. Infectious causes of granulomatous disease, including Mycobacterium tuberculosis, non-tuberculous mycobacteria, and fungal infections, were excluded through com-prehensive testing. The patient initially received conventional systemic corticosteroid therapy but developed treatment-related complications. Due to the need for sustained disease control, an alternative regimen combining low-dose corticosteroids with the selective JAK1 inhibitor abrocitinib was initiated.

Results: The patient showed significant clinical improvement following the combination therapy, with no observed treatment-related adverse events.

Conclusions: This case suggests that low-dose corticosteroids combined with a JAK1 inhibitor such as abrocitinib may represent a treatment option for patients with sarcoidosis.

目的:结节病是一种慢性、多系统肉芽肿性疾病,组织学上以非干酪化肉芽肿为特征。尽管有各种治疗选择,长期疾病控制仍然是一个重大的临床挑战。材料和方法:我们报告一例55岁女性结节病的诊断。皮肤和淋巴结活检显示非干酪化肉芽肿性炎症,胸部CT显示肺部受累。通过综合检测排除肉芽肿性疾病的感染性原因,包括结核分枝杆菌、非结核分枝杆菌和真菌感染。患者最初接受常规全身皮质类固醇治疗,但出现治疗相关并发症。由于需要持续的疾病控制,一种替代方案将低剂量皮质类固醇与选择性JAK1抑制剂阿布西替尼联合使用。结果:患者经联合治疗后临床表现明显改善,未见治疗相关不良事件。结论:本病例提示,低剂量皮质类固醇联合JAK1抑制剂如阿布替尼可能是结节病患者的一种治疗选择。
{"title":"Abrocitinib combined with low-dose corticosteroids in the management of tattoo-related cutaneous sarcoidosis: a case report.","authors":"Qingwei Geng, Junzhu Xu","doi":"10.1080/09546634.2025.2556487","DOIUrl":"https://doi.org/10.1080/09546634.2025.2556487","url":null,"abstract":"<p><strong>Purpose: </strong>Sarcoidosis is a chronic, multisystem granulomatous disorder characterized histologically by non-caseating granulomas. Despite the availability of various therapeutic options, long-term disease control remains a significant clinical challenge.</p><p><strong>Materials and methods: </strong>We report the case of a 55-year-old female diagnosed with sarcoidosis. Skin and lymph node biopsies revealed non-caseating granulomatous inflammation, and chest CT indicated pulmonary involvement. Infectious causes of granulomatous disease, including Mycobacterium tuberculosis, non-tuberculous mycobacteria, and fungal infections, were excluded through com-prehensive testing. The patient initially received conventional systemic corticosteroid therapy but developed treatment-related complications. Due to the need for sustained disease control, an alternative regimen combining low-dose corticosteroids with the selective JAK1 inhibitor abrocitinib was initiated.</p><p><strong>Results: </strong>The patient showed significant clinical improvement following the combination therapy, with no observed treatment-related adverse events.</p><p><strong>Conclusions: </strong>This case suggests that low-dose corticosteroids combined with a JAK1 inhibitor such as abrocitinib may represent a treatment option for patients with sarcoidosis.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2556487"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anatomical-based diagnosis and filler injection techniques: marionette line (static labiomandibular fold). 基于解剖的诊断和填充物注射技术:牵线木偶线(静态唇颌襞)。
Pub Date : 2025-12-01 Epub Date: 2025-02-02 DOI: 10.1080/09546634.2025.2452954
Gi-Woong Hong, Sky Wong, Song-Eun Yoon, Jovian Wan, Kyu-Ho Yi

Purpose: Marionette lines, also known as static labiomandibular folds, are common age-related perioral wrinkles that impact facial aesthetics, particularly in Asian populations. This article aims to examine the anatomical basis, etiology, and filler injection techniques used for treating marionette lines.

Materials and methods: The study reviews anatomical studies and clinical practices related to marionette lines. Anatomical observations focus on the position of the modiolus and its relationship to age-related changes. Treatment approaches are examined through a review of filler injection techniques, including supramuscular and submuscular fat layer targeting, as well as neurotoxin use for enhancing treatment outcomes.

Results: The review finds that the anatomical positioning of the modiolus in Asian populations predisposes them to increased susceptibility to commissural ptosis and wrinkle formation. Filler injections, particularly using a cannula for deeper layers, are effective for addressing volumetric loss in the supramuscular and submuscular layers. Neurotoxin injections into the depressor anguli oris muscle can enhance results by reducing downward force on the oral commissure.

Conclusions: Marionette lines are complex, multifactorial wrinkles that benefit from a multimodal treatment approach, combining dermal fillers and neurotoxins. Awareness of anatomical variations and proper injection techniques is crucial for achieving optimal aesthetic outcomes and minimizing risks.

目的:木偶纹,也被称为静态唇下颌骨褶皱,是一种常见的与年龄有关的影响面部美学的口周皱纹,特别是在亚洲人群中。本文旨在探讨解剖基础,病因和填充物注射技术用于治疗牵线木偶线。材料和方法:本研究综述了与牵线木偶线相关的解剖学研究和临床实践。解剖观察的重点是眼睑的位置及其与年龄相关变化的关系。通过对填充物注射技术的回顾,包括肌肉上和肌肉下脂肪层靶向,以及神经毒素用于提高治疗效果,检查了治疗方法。结果:回顾发现,亚洲人群中眼睑的解剖位置使他们易患关节下垂和皱纹形成。填充物注射,特别是在深层使用套管,对于解决肌肉上和肌肉下层的体积损失是有效的。神经毒素注射到降角口肌可以减少对口腔连接的向下作用力,从而提高疗效。结论:木偶纹是复杂的,多因素皱纹,受益于多模式治疗方法,结合真皮填充物和神经毒素。意识到解剖变异和适当的注射技术是实现最佳美学效果和最小化风险的关键。
{"title":"Anatomical-based diagnosis and filler injection techniques: marionette line (static labiomandibular fold).","authors":"Gi-Woong Hong, Sky Wong, Song-Eun Yoon, Jovian Wan, Kyu-Ho Yi","doi":"10.1080/09546634.2025.2452954","DOIUrl":"10.1080/09546634.2025.2452954","url":null,"abstract":"<p><strong>Purpose: </strong>Marionette lines, also known as static labiomandibular folds, are common age-related perioral wrinkles that impact facial aesthetics, particularly in Asian populations. This article aims to examine the anatomical basis, etiology, and filler injection techniques used for treating marionette lines.</p><p><strong>Materials and methods: </strong>The study reviews anatomical studies and clinical practices related to marionette lines. Anatomical observations focus on the position of the modiolus and its relationship to age-related changes. Treatment approaches are examined through a review of filler injection techniques, including supramuscular and submuscular fat layer targeting, as well as neurotoxin use for enhancing treatment outcomes.</p><p><strong>Results: </strong>The review finds that the anatomical positioning of the modiolus in Asian populations predisposes them to increased susceptibility to commissural ptosis and wrinkle formation. Filler injections, particularly using a cannula for deeper layers, are effective for addressing volumetric loss in the supramuscular and submuscular layers. Neurotoxin injections into the depressor anguli oris muscle can enhance results by reducing downward force on the oral commissure.</p><p><strong>Conclusions: </strong>Marionette lines are complex, multifactorial wrinkles that benefit from a multimodal treatment approach, combining dermal fillers and neurotoxins. Awareness of anatomical variations and proper injection techniques is crucial for achieving optimal aesthetic outcomes and minimizing risks.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2452954"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-communicable diseases comorbidities negatively impact the treatment outcomes among psoriasis patients: a longitudinal study in Shanghai, China. 非传染性疾病合并症对银屑病患者的治疗结果有负面影响:中国上海的一项纵向研究
Pub Date : 2025-12-01 Epub Date: 2025-07-25 DOI: 10.1080/09546634.2025.2536113
Quanruo Xu, Yuning Ding, Zhen Duan, Xiuqi Zhang, Ruiqi Cai, Xiangjin Gao, Rui Zhang, Ruiping Wang

Background: Psoriasis is frequently associated with non-communicable disease (NCD) comorbidities, prompting interest in how these concurrent conditions may influence psoriasis treatment outcomes.

Objectives: To assess NCD prevalence and their influence on psoriasis treatment outcomes.

Methods: From 2022 to 2024, we recruited psoriasis patients in Shanghai Skin Disease Hospital. Data on demographic features, NCD comorbidities and treatment outcomes at week 4 and week 8 were systematically collected through questionnaire, physical examination, and clinical severity assessment (psoriasis area and severity index [PASI], body surface area [BSA], physician's global assessment [PGA]).

Results: Among 1116 patients, 48.4% had at least one NCD comorbidity. NCD-free patients exhibited higher PASI50 response rates at both week 4 (46.5 vs. 39.1%) and week 8 (72.2 vs. 70.9%). Log binomial regression revealed that NCDs significantly reduced the likelihood of achieving PASI50 at week 4 (relative risk [RR] = 0.84, 95% confidence interval [CI]: 0.73-0.96), with a similar but non-significant trend at week 8 (RR = 0.98, 95% CI: 0.92-1.06).

Conclusion: NCDs negatively impact early treatment outcomes in psoriasis patients. So we propose that dermatologists should integrate systematic NCD management into psoriasis treatment regimen.

背景:牛皮癣经常与非传染性疾病(NCD)合并症相关,这些合并症如何影响牛皮癣治疗结果引起了人们的兴趣。目的:评估非传染性疾病患病率及其对银屑病治疗效果的影响。方法:于2022 - 2024年在上海皮肤病医院招募银屑病患者。通过问卷调查、体格检查和临床严重程度评估(牛皮癣面积和严重程度指数[PASI]、体表面积[BSA]、医生总体评估[PGA])系统收集第4周和第8周的人口统计学特征、非传染性疾病合并症和治疗结果数据。结果:1116例患者中,48.4%的患者至少有一种非传染性疾病合并症。无非传染性疾病患者在第4周(46.5 vs 39.1%)和第8周(72.2 vs 70.9%)均表现出更高的PASI50缓解率。对数二项回归显示,非传染性疾病显著降低了患者在第4周达到PASI50的可能性(相对风险[RR] = 0.84, 95%可信区间[CI]: 0.73-0.96),在第8周也有类似但不显著的趋势(RR = 0.98, 95% CI: 0.92-1.06)。结论:非传染性疾病对银屑病患者的早期治疗结果有负面影响。因此,我们建议皮肤科医生将系统的非传染性疾病管理纳入银屑病治疗方案。
{"title":"Non-communicable diseases comorbidities negatively impact the treatment outcomes among psoriasis patients: a longitudinal study in Shanghai, China.","authors":"Quanruo Xu, Yuning Ding, Zhen Duan, Xiuqi Zhang, Ruiqi Cai, Xiangjin Gao, Rui Zhang, Ruiping Wang","doi":"10.1080/09546634.2025.2536113","DOIUrl":"https://doi.org/10.1080/09546634.2025.2536113","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is frequently associated with non-communicable disease (NCD) comorbidities, prompting interest in how these concurrent conditions may influence psoriasis treatment outcomes.</p><p><strong>Objectives: </strong>To assess NCD prevalence and their influence on psoriasis treatment outcomes.</p><p><strong>Methods: </strong>From 2022 to 2024, we recruited psoriasis patients in Shanghai Skin Disease Hospital. Data on demographic features, NCD comorbidities and treatment outcomes at week 4 and week 8 were systematically collected through questionnaire, physical examination, and clinical severity assessment (psoriasis area and severity index [PASI], body surface area [BSA], physician's global assessment [PGA]).</p><p><strong>Results: </strong>Among 1116 patients, 48.4% had at least one NCD comorbidity. NCD-free patients exhibited higher PASI<sub>50</sub> response rates at both week 4 (46.5 <i>vs.</i> 39.1%) and week 8 (72.2 <i>vs.</i> 70.9%). Log binomial regression revealed that NCDs significantly reduced the likelihood of achieving PASI<sub>50</sub> at week 4 (relative risk [RR] = 0.84, 95% confidence interval [CI]: 0.73-0.96), with a similar but non-significant trend at week 8 (RR = 0.98, 95% CI: 0.92-1.06).</p><p><strong>Conclusion: </strong>NCDs negatively impact early treatment outcomes in psoriasis patients. So we propose that dermatologists should integrate systematic NCD management into psoriasis treatment regimen.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2536113"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients. 纳洛酮成功治疗哈雷-哈雷病2例报告及阿片受体拮抗剂治疗哈雷-哈雷病疗效文献综述
Pub Date : 2025-12-01 Epub Date: 2025-01-22 DOI: 10.1080/09546634.2025.2453597
Junyou Zheng, Zhimin Duan, Beilei Xu, Hao Song, Jianbing Wu, Fang Fang, Nan Sheng, Chengrang Li

Background: Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the ATP2C1 gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.

Objective: To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.

Methods: Two patients with biopsy-proven HHD received naloxone (2 mg/d, via intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.

Results: Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.

Conclusion: Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.

背景:海利-海利病(HHD)是一种遗传性水疱病,由ATP2C1基因编码的高尔基体中钙转运蛋白突变引起。在临床上,HHD主要表现为松弛的囊泡、水疱、糜烂、裂隙和浸渍,主要发生在三节间区。一些病人对常规治疗仍然难以治愈。此前,一系列的报道已经证实纳曲酮是这些患者的有效选择。然而,在中国,一些医院没有纳曲酮,一些患者负担不起。目的:确认纳曲酮作为HHD的治疗选择,并评价纳曲酮治疗HHD患者的有效性和安全性。方法:2例活检证实的HHD患者接受纳洛酮(2mg /d,静脉滴注)治疗。我们对两名患者进行随访,评估皮肤病变的变化并拍摄照片。我们检索PubMed数据库,检索关键词为“海利-海利病”或“良性家族性天疱疮”,检索关键词为“纳曲酮”或“纳洛酮”,查阅英文文献报道,分析纳曲酮的疗效和安全性。结果:2例患者服用纳洛酮后2周内病情完全缓解,无不良反应。纳曲酮治疗HHD的总缓解率约为80%,无严重不良反应。结论:纳曲酮治疗HHD有效、安全。纳洛酮,纳曲酮的类似物,也可以有效和安全地治疗HHD,可能为难治性HHD患者提供新的治疗选择。
{"title":"Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients.","authors":"Junyou Zheng, Zhimin Duan, Beilei Xu, Hao Song, Jianbing Wu, Fang Fang, Nan Sheng, Chengrang Li","doi":"10.1080/09546634.2025.2453597","DOIUrl":"10.1080/09546634.2025.2453597","url":null,"abstract":"<p><strong>Background: </strong>Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the <i>ATP2C1</i> gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.</p><p><strong>Objective: </strong>To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.</p><p><strong>Methods: </strong>Two patients with biopsy-proven HHD received naloxone (2 mg/d, <i>via</i> intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.</p><p><strong>Results: </strong>Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.</p><p><strong>Conclusion: </strong>Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2453597"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity. 用生物制剂治疗的小儿和青年牛皮癣患者的性别差异:不良事件和疾病活动性的差异
Pub Date : 2025-12-01 Epub Date: 2025-07-23 DOI: 10.1080/09546634.2025.2532672
Malak Al-Gawahiri, Liana Barenbrug, Ewald M Bronkhorst, Elke M G J de Jong, Juul M P A van den Reek, Marieke M B Seyger

Introduction: Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study.

Methods: Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children's) Dermatology Life Quality Index ((C)DLQI) scores between sexes.

Results: We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males.

Conclusion: Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.

简介:银屑病成年患者生物治疗结果的性别差异是众所周知的。本研究调查了现实世界中使用生物制剂的儿科和青年牛皮癣患者的潜在性别差异。结果:纳入使用生物制剂的117例儿科(女性65例)和243例青壮年(女性124例)患者(753.4观察年)。与女性相比,年轻成年男性在生物起始时的PASI明显更高,儿科患者也有同样的趋势。在儿科和年轻成人患者中,女性的不良事件发生率高于男性。治疗第一年的药物生存期、PASI和(C)DLQI病程在儿科和年轻成年女性和男性之间具有可比性。结论:了解儿童和青年牛皮癣患者的性别差异(起始PASI和不良事件发生率)对于及时启动和调整适当的治疗具有重要意义。
{"title":"Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity.","authors":"Malak Al-Gawahiri, Liana Barenbrug, Ewald M Bronkhorst, Elke M G J de Jong, Juul M P A van den Reek, Marieke M B Seyger","doi":"10.1080/09546634.2025.2532672","DOIUrl":"https://doi.org/10.1080/09546634.2025.2532672","url":null,"abstract":"<p><strong>Introduction: </strong>Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study.</p><p><strong>Methods: </strong>Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children's) Dermatology Life Quality Index ((C)DLQI) scores between sexes.</p><p><strong>Results: </strong>We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males.</p><p><strong>Conclusion: </strong>Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2532672"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the environmental impact of medication packaging in dermatology. 皮肤科药品包装对环境影响的评价。
Pub Date : 2025-12-01 Epub Date: 2025-07-18 DOI: 10.1080/09546634.2025.2528719
Georgia Marquez-Grap, Andrea Leung, Payton Smith, Tina Bhutani
{"title":"Evaluation of the environmental impact of medication packaging in dermatology.","authors":"Georgia Marquez-Grap, Andrea Leung, Payton Smith, Tina Bhutani","doi":"10.1080/09546634.2025.2528719","DOIUrl":"https://doi.org/10.1080/09546634.2025.2528719","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2528719"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The Journal of dermatological treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1